Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer

Show simple item record 2012-03-30T05:31:19Z 2012-03-30T05:31:19Z 2011-09-23
dc.identifier.citation Infectious Agents and Cancer. 2011 Sep 23;6(Suppl 2):S7
dc.description.abstract Abstract Background Androgen deprivation therapy (ADT) has been reported to reduce the bone mineral density (BMD) in men with prostate cancer (CaP). However, Afro-Caribbeans are under-represented in most studies. The aim was to determine the effect of androgen deprivation therapy (ADT) on the bone mineral density (BMD) of men with prostate cancer in Jamaica. Methods The study consisted of 346 Jamaican men, over 40 years of age: 133 ADT treated CaP cases (group 1), 43 hormone-naand#239;ve CaP controls (group 2) and 170 hormone naand#239;ve controls without CaP (group 3). Exclusion criteria included metastatic disease, bisphosphonate therapy or metabolic disease affecting BMD. BMD was measured with a calcaneal ultrasound and expressed in S.D. units relative to young adult men (T score), according to the World Health Organization definition. Patient weight, height and BMI were assessed. Results Mean and#177; sd, age of patients in group 1 (75and#177; 7.4 yrs) was significantly greater than groups 2 and 3 (67 and#177; 8.1 yrs; 65and#177;12.0 yrs). There was no significant difference in weight and BMI between the 3 groups. . The types of ADT (% of cases, median duration in months with IQR) included LHRH (Luteinizing hormone releasing hormone) analogues (28.6%, 17.9, IQR 20.4), oestrogens (9.8%, 60.5, IQR 45.6) anti-androgens (11.3%, 3.3, IQR 15.2) and orchiectomy (15.7%, 43.4, IQR 63.9). Unadjusted t score of group 1, mean and#177; sd, (-1.6and#177; 1.5) was significantly less than group 2 (-0.9and#177;1.1) and group 3 (-0.7and#177;1.4), p andlt;0.001. Ninety three (69.9%), 20 (45%) and 75 (42%) of patients in groups 1, 2 and 3 respectively were classified as either osteopenic or osteoporotic (pandlt;0.001). Adjusting for age, there was a significant difference in t scores between groups 1 and 2 as well as between groups 1 and 3 (pandlt;0.001). Compared with oestrogen therapy and adjusting for duration of therapy, the odds of low bone mineral density (osteopenia or osteoporosis) with LHRH analogue was 4.5 (95%CI, 14.3 to 3.4); with anti-androgens was 5.9 (95%CI, 32.7 to 5); with orchiectomy was 7.3 (95%CI, 30 to 5.8) and multiple drugs was 9.2 ((95%CI, 31 to 7.1). Conclusions ADT is associated with lower BMD in Jamaican men on hormonal therapy for prostate cancer.
dc.title Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
dc.type Journal Article 2012-03-30T05:31:19Z
dc.description.version Peer Reviewed
dc.language.rfc3066 en
dc.rights.holder et al.; licensee BioMed Central Ltd.

Files in this item

Files Size Format View
1750-9378-6-S2-S7.xml 45.50Kb XML View/Open
1750-9378-6-S2-S7.pdf 913.8Kb PDF Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search UWISpace

Advanced Search


My Account